{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_codes_comments in Code Comments (approximate match)
Status:
Investigational
Source:
NCT01439971: Phase 1 Interventional Completed Hemophilia A
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:exbivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01135108: Phase 2 Interventional Completed Spinal Cord Injury
(2009)
Source URL:
Class:
PROTEIN
KAI 1678 is a first-in-class, isoenzyme selective, a small peptide inhibitor of protein kinase C epsilon. It was in development for the treatment of neuropathic and postoperative pain. However, KAI-1678 treatment results were negative.
Status:
Investigational
Source:
INN:libivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04176133: Phase 2 Interventional Completed Healthy
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01392547: Phase 3 Interventional Completed Congenital Bleeding Disorder
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00484757: Not Applicable Interventional Unknown status Narcolepsy
(2007)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:381712
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:906922
Source URL:
Class:
PROTEIN
